


### Extending the Boundaries of Targeted Cancer Therapies with Radio-DARPins and Next-Gen Immune Cell Engagers

Patrick Amstutz, CEO

JPMorgan HealthCare Conference

January 15, 2025



Nasdaq, SIX Swiss Exchange: MOLN

### Disclaimer

This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates, expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials, the potential therapeutic and clinical benefits of Molecular Partners' product candidates, the selection and development of future programs, and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2024 and its expectation of its current cash runway. These statements may be identified by words such as "guidance", "believe", "expect", "may", "plan", "potential", "will", "would" and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners' reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners' ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners' ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners' product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners' product candidates; the potential that Molecular Partners' product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners' preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners' plans and development of any new indications for its product candidates; Molecular Partners' commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners' intellectual property position; Molecular Partners' ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may impact Molecular Partners' financial and business projections and guidance and may cause Molecular Partners' actual results and outcomes to materially differ from its guidance; and other risks and uncertainties that are described in the Risk Factors section of Molecular Partners' Annual Report on Form 20-F for the fiscal year ended December 31, 2023, filed with Securities and Exchange Commission (SEC) on March 14, 2024 and other filings Molecular Partners makes with the SEC. These documents are available on the Investors page of Molecular Partners' website at www.molecularpartners.com.


Any forward-looking statements speak only as of the date of this presentation and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.



### Molecular Partners at a Glance

Extending the Boundaries of Targeted Cancer Therapies

**DARPin** Designed Ankyrin Repeat Protein



### **Our Pipeline: Patient Value**

- Differentiated Assets with focus in Oncology, including
- MP0533, MP0712 & more for patients across indications with high unmet medical need

#### **Our Capabilities: Technology, Team, Collaborations**


- Proprietary DARPin Platforms, including Radio-DARPins and Switch / T cell engagers
- Strong international team to execute up to clinical POC and
- Global partnerships to access technology & capabilities (Orano Med)

#### **Our Company: MOLN**

- Well financed into 2027 through key value inflection points (CHF ~149 M)
- Operations & listing in Switzerland (SIX, 2014) and US (Nasdaq, 2021)



### The DARPin Modality and Molecular Partners' Strategy



#### What we invented

- New class of therapeutics: Designed Ankyrin Repeat Proteins (DARPins)
- DARPins close the gap between small molecules and antibodies
- 7 clinical-stage compounds, >2500 patients treated

### How we apply it


- **Unique DARPin solutions**, not addressable by antibody designs
- Demonstrate true patient value with early clinical readouts
- Combine our capabilities with world-class partners




### **DARPin Platforms to Build Therapeutics**

**Radio-DARPin Therapy** 

**Next-Gen Immune Cell Engagers** 







### Pipeline

MODALITY	CANDIDATE	RESEARCH	PRE-CLINICAL	PHASE 1	PHASE 2	PARTNER
Radio–DARPin Therapy (RDT)	MP0712 (DLL3)	SCLC & NETs <sup>212</sup> Pb - DLL3	Co-development*			
	RDT x MSLN	Ovarian <sup>212</sup> Pb - MSLN	Co-development*			→ oranomed
	Undisclosed Programs	Solid Tumors	Up to 8 programs*			
	Undisclosed Programs	Solid Tumors	2 partnered programs			U NOVARTIS
Next-Gen Immune Cell Engagers	MP0533	<b>r/r AML and AML/MD</b> CD33 x CD123 x CD7				
	Switch-DARPin T-cell Engager	CD3 x costim x TAAs				
	MP0621	<b>HSCT</b> cKit x CD16a x CD47				
	MP0317	Advanced Solid Tum FAP x CD40	ors			To partner with leading academic institution for IIT




\*The co-development agreement with Orano Med includes up to 10 RDT programs, including MP0712.

AML, acute myeloid leukemia; DLL3, Delta-like ligand 3; HSCT, hematopoietic stem cell transplant; IIT, investigator-initiated trial; MDS, 6 myelodysplastic syndrome; MSLN, mesothelin; NET, neuroendocrine tumor; r/r, relapsed/refractory; SCLC, small cell lung cancer.




# Radio-DARPin Therapy & MP0712

Custom-engineered to create vectors ideal for radiopharmaceuticals




### Targeted Radiotherapy: "Old" Modality Turned Hot Through Precision



- "See what you treat" & "treat what you see"
- Enables early validation or kill point
- Proven clinical benefit for oncology patients
- Limitation: current vectors not applicable to all targets
- **Opportunity:** Broaden the target space with next generation vectors
- DARPins have ideal properties as vectors for radioisotope delivery

Example of a prostate cancer patient with extensive bone metastasis treated with <sup>225</sup>Ac-PSMA-617:



July 2017, PSA = 782 ng/ml PET/CT, 68Ga-PSMA-11

May 2018, PSA = 0.04 ng/ml PET/CT, 68Ga-PSMA-11

8




PET/CT scan pictures adapted from Sathekge M, et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging 46, 129–138 (2019). <u>https://doi.org/10.1007/s00259-018-4167-0.</u>

### Radio-DARPins as Versatile Therapeutic Candidates

Combining versatile DARPin features with the power of <sup>212</sup>Pb for next-gen Targeted Alpha Therapy

#### DARPin: IDEAL VECTOR FOR RADIOPHARMACEUTICALS





<sup>212</sup>Pb: ALPHA-EMITTING

THERAPEUTIC ISOTOPE


### Global Partnership to Develop <sup>212</sup>Pb Radio-DARPin Therapeutics

Combining DARPin versatility with the power of <sup>212</sup>Pb for next-gen Targeted Alpha Therapy

#### MOLECULAR PARTNERS PIONEERS of DARPIN THERAPEUTICS



- Proprietary DARPins as ideal vectors for radiotherapeutics
- Manufacturing capabilities of DARPins
- Operational excellence in clinic



DARPin Engine: Rapid selection, development & manufacturing of candidates

INDIANA, US: Industrial scale manufacturing Global shipping hub ATLab US

TEXAS, US: Preclinical development GMP supply for early clinical phases



- World class technologies combined
- Ability for rapid candidate testing/cycling
- Strategic impact: up to 10 radiotherapy products

#### <sup>212</sup>Pb RADIO-DARPin CANDIDATES



#### ORANO MED

#### **PIONEERS of TARGETED ALPHA THERAPY**

- Unique independent supply of <sup>212</sup>Pb as alpha emitting therapeutic isotope
- Large scale GMP manufacturing capabilities
- Strong pre-clinical and clinical expertise in radiotherapeutics

212Pb 10.6 h

$\subseteq$ $\ni$	PAPA
	IPPP

22,000 drums of <sup>232</sup>Th, providing virtually unlimited raw starting material for <sup>212</sup>Pb production

SWITZERLAND: Preclinical assessment DARPin engine, fast & high throughput

FRANCE: <sup>212</sup>Pb starting material ATLab Europe





### MP0712, the first <sup>212</sup>Pb-DLL3 Targeted Radiotherapeutic for SCLC

#### SCLC: critical unmet need, limited treatment options


- Median progression free survival (mPFS) ~3 months<sup>1,2</sup>
- 5y overall survival (OS) ~3%<sup>1,2</sup>

#### **DLL3: a validated target for SCLC**

- Expressed in >85% of SCLC patients<sup>3</sup> and in neuroendocrine cancers
- No expression in healthy tissues
- Tarlatamab<sup>4</sup>, approved DLL3 targeting drug (T cell engager)
  - ORR ~40%, DOR 9.7 months, PFS 4.3 months

#### MP0712: targeted delivery of alpha radiation with <sup>212</sup>Pb

- DLL3 DARPin optimized for selective delivery of payload to tumor
- <sup>212</sup>Pb payload: high energy alpha emissions in short time frame, works with low target copy number (no need for internalization)
- Potential for combinations with immunotherapy






1.Treatment of refractory and relapsed small cell lung cancer, UpToDate; 2. SEER; 3. Rojo et al., Lung Cancer 2020; 4. Phase 2 DeLLphi-301 study (NCT05060016). DOR, duration of response; HLE, half-life extension; ORR, overall response rate; SCLC, small cell lung cancer.



### MP0712: Attractive Biodistribution Profile in Clinically-Relevant Model




- MP0712 reached T:K ratios > 2 in mouse model matching clinically relevant DLL3 expression levels
- Selective uptake in DLL3-expressing tumors confirmed high target specificity of MP0712 (data not shown)

MOLECULAR partners Croset et al, EANM 2024 (oral presentation) Lizak et al, SNMMI 2024 (oral presentation) hDLL3-MC38 and NCI-H82 mouse models:  ${}^{212}$ Pb-DOTAM-DARPin - single injection - dose : 10 µCi (0.01 mg/kg)



### MP0712: Potent Efficacy at Clinically-Relevant Dose




- MP0712 induces complete and durable tumor regression in NCI-H82 tumor model at 10µCi injected every week
- At day 63, complete tumor regression is seen for ~70% of mice at <u>4x 10µCi</u> and ~20% of mice at <u>8x 5µCi</u>




Efficacy study in NCI-H82 tumor model / MP0712 and negative control injected 4 x 10µCi at 0.01mg/kg or 8 x 5µCi at 0.01mg/kg every 1; 10 µCi = 370 kBq



### MP0712: Favorable Safety Profile at Clinically-Relevant Dose



- Complete recovery of body weight loss after 10 days
- Complete recovery of hematologic profile after 28 days
- MP0712 treatment up to 30 µCi / 1.11 MBq well tolerated





MP0712 DRF study done in WT mice / <sup>212</sup>Pb-DOTAM-DARPin injected once from 10 to 60µCi. WBC, white blood cells; LYMP, lymphocytes, MON, monocytes; NEU, neutrophils.



### Outline of MP0712 Clinical Development Strategy


- Patients: Focus on Small Cell Lung Cancer (SCLC), secondly on Neuro Endocrine Prostrate (NEPC)
- Biodistribution and dosimetry Phase 0 and Phase 1 studies to start in H2 2025, initial clinical data by YE

#### **IMAGING & DOSIMETRY**

**Phase 0 – Imaging** of **MP0712 with** <sup>203</sup>**Pb** (biodistribution/dosimetry) Main objective: Imaging and Full Dosimetry to support dose strategy for <sup>212</sup>Pb N = 5-10 patients

#### Purpose:

➔ Build confidence to reach relevant therapeutic level in tumor lesions







### <sup>212</sup>Pb x MSLN Targeted Radio-DARPin for Ovarian Cancer

Combining distinctive DARPin features with the power of <sup>212</sup>Pb for next-gen targeted alpha therapy

#### **Ovarian Cancer (OC): high medical need and marginal progress**


- > 50% patients die within 5y post-diagnosis (diagnosis often in late stage)
- Poor treatment options: ~80% recurrence rate post 1L chemo, limited 2L options (FR-alpha targeted Tx relevant for only 40% patients)

#### Mesothelin (MSLN): a promising target for OC as 1<sup>st</sup> indication

- Highly expressed in OC (>80% prevalence), expression maintained in metastases
- Shed MSLN detected in serum of OC patients, might limit efficacy of MSLNtargeted therapies<sup>1,2,3,4</sup> (e.g., CAR T/NK, ADC, TCE in development)

#### RDT x MSLN: targeted delivery of alpha radiation with <sup>212</sup>Pb


- MSLN DARPin targets membrane-proximal epitope (and not shed MSLN)
- <sup>212</sup>Pb payload: high energy alpha emissions in short time frame
- Potential for combinations with immunotherapy (incl. next-gen TCEs)






### DARPin activity is maintained despite shed MSLN











## Continue to Leverage DARPin Differentiation to Build Portfolio of Radio-DARPin candidates




Selectivity for membrane-bound antigen vs shed antigen for high tumor uptake

Selectivity to antigens with **high surface homology** to other targets



2in1 DARPin



**Bi-specific** DARPins to achieve **broader distribution in tumors** & **overcome heterogeneity**, especially for targeted alpha therapy






## MP0533

Tetra-specific T-cell Engager for AML


### MP0533 Enables Avidity-Driven Selective Killing of AML Cells

#### AML-associated antigens are also expressed on healthy cells



- AML bears a high risk of relapse due to persistent LSCs
- AML cell population is heterogeneous → differentiation from healthy cells (e.g., HSCs) feasible through their co-expression of CD33, CD123, CD70

#### MP0533: avidity-driven selectivity and T cell-mediated killing






- MP0533 designed to induce T cell-mediated killing preferentially when 2 or 3 AML-associated antigens are co-expressed
- Potential to kill all AML cells (blasts and LSCs) despite heterogeneity, ensuring long-term disease control



### MP0533 Treatment and Clinical Response



**Dose Escalation (DR 1–7)** 

#### **DR 1–7:** 4 responders reported, manageable safety

#### Legend

Response (2022 ELN<sup>1</sup>) was assessed every 4 weeks until disease progression and results are presented as: 🖈 CR 🗙 CRi ○ No ELN response Patients with ongoing treatment at data cut-off Patients who discontinued treatment Arrows at the top indicate MP0533 administration at D1, D5, D8, D12 (DR 8 only), D15 and weekly thereafter Step-up dosing at DR 1–7 ↓ D12 dose at DR 8


Color changes in grey: start of a new 28-day cycle




Data cut-off: 16 December 2024 Preliminary data as study is ongoing, subject to final data validation.

1. Döhner et al. Blood 2022;140(12)1345-77. CR, complete response; CRi, CR with incomplete hematologic recovery; 21 ELN, European LeukemiaNet; MLFS, morphologic leukemia-free state.

# Improved MP0533 exposure at DR 8 with steeper and denser step-up dosing regimen




### MP0533 Phase 1/2a Study in Patients with R/R AML/MDS Protocol amendment to optimize MP0533 exposure






# Improved MP0533 exposure at DR 8 with steeper and denser step-up dosing regimen




### MP0533 Treatment and Clinical Response

Dose Escalation (DR 1–7)







DR 1-7: 4 responders reported, manageable safety

**DR 8:** At least 3 responders and manageable safety reported todate, evaluation and dosing on-going

DR 9+ (further dose densification): update in 2025

#### Legend

 Response (2022 ELN¹) was assessed every 4 weeks until disease progression and results are presented as:

 ★ CR
 ★ CRi
 ★ MLFS
 ○ No ELN response

 ▶ Patients with ongoing treatment at data cut-off
 Patients who discontinued treatment

 Arrows at the top indicate MP0533 administration at D1, D5, D8, D12 (DR 8 only), D15 and weekly thereafter

 ↓ Step-up dosing at DR 1–7
 ↓ D12 dose at DR 8

 ↓ Color changes in grey: start of a new 28-day cycle



Data cut-off: 16 December 2024 Preliminary data as study is ongoing, subject to final data validation. 1. Döhner et al. Blood 2022;140(12)1345-77. CR, complete response; CRi, CR with incomplete hematologic recovery; ELN, European LeukemiaNet; MLFS, morphologic leukemia-free state.



### **Switch-DARPin Platform**

Targeted and conditional activation of immune cells

### Overcoming Limitations of Current T Cell Engager platforms with Combinable DARPin Solutions

#### **Challenges with current TCEs**

#### Lack of tumor-specific targets

Multi-specific antibody generation is technically challenging


#### Narrow therapeutic window

- CRS and on-target toxicity limit dosing
- Mitigation strategies (e.g. lower CD3 affinity) lead to lower activity
- Conditional activation depends on the environment (e.g proteases)

#### Impaired T cell function

- T cell exhaustion & immune suppression limit activity
- Co-stimulation comes with safety challenges

### **DARPin TCE Solutions**






27

### Logic-gated Switch-DARPins for Next-Gen T Cell Engagers


Swiss knives for targeted and conditional immune activation






### CD3 Switch-DARPin for Next-gen TCEs with Enhanced Function

Tackling current limitations of TCEs in solid tumors





### Switch-DARPin leads to tumor regression pre-clinically



- EpCAM-MSLN-CD2/CD3 Switch induces tumor regression more efficiently than a MSLN-CD3 engager (Tritac).
- Non switched CD2/CD3 DARPin is not efficacious, likely due to loss of CD45+ T cells as a result of T cell fratricide
- Masking CD3 DARPin allows for "silent" T cell engager (TCE) in the periphery while demonstrating potent efficacy on tumors, potentially allowing for better safety profile of TCEs

MOLECULAR<br/>O artnersOVCAR-3 s.c. model: 10 mice/group, 2 PBMC donors engrafted at 100mm<sup>3</sup>,<br/>average +/- SEM, two-way ANOVA. Daily i.v. treatment from d49: DARPin @<br/>3.8mg/kg, Tritac @ 0.25 mg/kg



### Outlook

### 2025 Outlook and Upcoming Milestones

MP0712	<ul> <li>IND applications of MP0712, <sup>212</sup>Pb x DLL3 RDT, for phase 0 and 1 studies, H1 2025</li> <li>First-in-Human studies start in H2 2025</li> <li>Initial clinical data H2 2025</li> </ul>
Radio-DARPin Therapy (RDT)	<ul> <li>MSLN update at AACR 2025, therapeutic candidate selection</li> <li>Additional <sup>212</sup>Pb x RDT programs nominated, in collaboration with Orano Med</li> </ul>
MP0533	<ul> <li>Comprehensive clinical data from Phase 1 cohort 8 in H1 2025</li> <li>Protocol amendment acceptance and implementation of improved dosing regime, H1 2025</li> <li>Data from cohorts with amended dosing scheme in H2 2025</li> </ul>
Switch-DARPin	<ul> <li>Preclinical update on CD3 Switch T cell engager at AACR 2025</li> <li>Evaluation of partnering opportunities with Switch platform, including MP0621 (cKit)</li> </ul>

CHF ~149 million cash\* (incl. short-term time deposits) ensures funding into 2027



32



Twenty Years of Pioneering DARPin Therapeutics for Patients

## **Thank You**





